IBRX News and Press, ImmunityBio Inc. From 06/07/24

2024-06-07 10:10:00 ET June 7, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical the...

ImmunityBio, Inc. ( NASDAQ: IBRX ) announced today that its 2024 Annual Meeting of Stockholders will be held on Tuesday, June 11, 2024 at 9:30 a.m. Pacific Time. The Annual Meeting will be held in a virtual-only format and there will not be a physical location for the Annual Meeting. Stockhol...

2024-06-06 15:09:22 ET Summary ImmunityBio's flagship product, Anktiva, has been launched in the market for the treatment of bladder cancer, with strong clinical data supporting its efficacy. The company is well-prepared for the launch, with a strong sales force, established distr...

2024-06-04 07:06:40 ET More on ImmunityBio, LadRx, etc. ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains ImmunityBio: FDA Approval Gets Ball Rolling Towards Next Set Of Indications ImmunityBio Lights Up: Anktiva's FDA Nod Sha...

2024-05-26 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T cells, and Memory T cells The clinical findings of a durable complete response and implications for nonmuscle invasive bladder cancer patients with the launch of ANKTIV...

2024-05-17 04:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-10 09:53:04 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips ImmunityBio (NASDAQ: IBRX ) just reported results for the first quarter of 2024. ImmunityBio reported earnings per share of -20 cents. This was below the analyst estimate ...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...